Acetaminophen Caffeine Pyrilamine

證據等級: L5

預測適應症: 0 個

Acetaminophen / Caffeine / Pyrilamine: Drug Repurposing Evaluation Report

One-Sentence Summary

Acetaminophen / Caffeine / Pyrilamine is a well-known over-the-counter combination used for analgesia, antipyresis, and antihistamine relief (commonly found in cold and menstrual pain products). The TxGNN model returned no predicted new indications for this combination, likely because the drug combination lacks a mapped DrugBank ID in the knowledge graph. Without predictions or regulatory registration data, this candidate currently cannot be evaluated through the standard repurposing workflow.

Quick Overview

Item	Content
Original Indication	Not recorded in this Evidence Pack
Predicted New Indication	No predictions available
TxGNN Prediction Score	—
Evidence Level	Not evaluable (no predictions in system)
Taiwan Market Status	✗ Not marketed
Number of Licenses	0
Recommended Decision	Hold

Why Evaluation Cannot Proceed

This combination drug consists of three components:

Acetaminophen (Paracetamol): Centrally-acting analgesic and antipyretic; inhibits prostaglandin synthesis in the CNS.
Caffeine: Methylxanthine; potentiates the analgesic effect of acetaminophen by approximately 40% (adjuvant role), increases alertness via adenosine receptor antagonism.
Pyrilamine (Mepyramine): First-generation H1-antihistamine; provides antiallergic and mild sedative effects.

This combination is pharmacologically rational for treating headache, fever, and allergy-related symptoms. However, the TxGNN pipeline requires a mapped DrugBank ID to traverse the knowledge graph and generate repurposing candidates. Since drugbank_id is null in this Evidence Pack, the model could not locate this combination as a single entity in the graph.

The absence of predictions reflects a data pipeline issue, not necessarily a lack of repurposing potential for the individual components.

Clinical Trial Evidence

Currently no related clinical trials registered under this specific combination in the Evidence Pack.

Literature Evidence

Currently no related literature available in the Evidence Pack.

Taiwan Market Information

This drug combination has 0 registered licenses in Taiwan and is currently not marketed. No authorization records are available to display.

Safety Considerations

Please refer to the package insert for safety information.

Note: Safety data (warnings, contraindications, drug-drug interactions) could not be retrieved for this combination entry. Individual component safety profiles should be consulted separately via DrugBank or official prescribing information:

Acetaminophen: hepatotoxicity risk at high doses; interactions with warfarin and alcohol

Caffeine: CNS stimulation; caution in anxiety disorders and cardiovascular disease

Pyrilamine: anticholinergic effects; CNS depression; avoid in elderly and patients with urinary retention or glaucoma

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model produced no repurposing predictions because the combination lacks a mapped DrugBank ID, making knowledge graph traversal impossible. Without predictions, there is no scientifically grounded repurposing hypothesis to evaluate.

To proceed, the following is needed:

Resolve DrugBank mapping: Determine whether to evaluate each component (Acetaminophen, Caffeine, Pyrilamine) individually rather than as a fixed combination; retrieve individual DrugBank IDs (DB00316, DB00201, DB01237 respectively)
Re-run TxGNN pipeline using individual component IDs to generate per-component repurposing predictions
Retrieve MOA data from DrugBank API for each component to enable mechanistic plausibility analysis
Clarify original indication scope: Document the combination’s approved uses (e.g., tension headache, cold/flu symptoms, dysmenorrhea) in the source regulatory database
Confirm regulatory intent: If the target market is Taiwan, establish whether individual components or the fixed-dose combination is the object of evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.